Related Experiment Video
Updated: Aug 17, 2025
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
2.5K
[Cardiac contractility modulation in heart failure with reduced ejection fraction treatment]
I A Chugunov1, Yu V Mareev2, M Fudim3
1National Medical Research Center of Therapy and Preventive Medicine.
Kardiologiia
|December 15, 2022
Summary
Cardiac contractility modulation (CCM) offers moderate quality of life improvements for heart failure with reduced ejection fraction (HFrEF) patients. However, its effects on reverse remodeling and survival require further investigation through randomized clinical trials.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Heart failure with reduced left ventricular ejection fraction (HFrEF) presents significant morbidity and mortality challenges.
- Despite advancements, high mortality and recurrent decompensated heart failure necessitate novel treatment strategies.
- Cardiac contractility modulation (CCM) is an emerging therapy for HFrEF management.
Approach:
- Review of available randomized clinical trials (RCTs) and observational studies on CCM efficacy.
- Assessment of CCM's impact on patient well-being, quality of life, left ventricular (LV) reverse remodeling, hospitalizations, and mortality.
- Identification of knowledge gaps and areas for future research.
Key Points:
- CCM demonstrates efficacy in improving patient well-being and quality of life in HFrEF.
- Evidence for CCM-induced LV reverse remodeling is primarily from experimental and observational data, lacking confirmation in RCTs.
- RCTs have not shown significant improvements in LV ejection fraction (EF) or overall prognosis with CCM therapy.
Conclusions:
- CCM provides moderate quality of life benefits for HFrEF patients.
- Further RCTs are essential to definitively evaluate CCM's effects on reverse remodeling and survival rates.
- The precise role of CCM within the comprehensive treatment of HFrEF remains to be established.
More Related Videos
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.6K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.5K
Related Concept Videos
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
482
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
482
01:22Heart Failure VI: Adjunct Therapies
23
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
23
01:29Cardiomyopathy V: Interprofessional Care
25
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
25
01:30Cardiomyopathy II: Dilated Cardiomyopathy
19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
01:26Heart Failure Drugs: Inotropic Agents
667
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
667